Retatrutide Cost: There Is No List Price Because It Is Not Approved

There is no lawful U.S. list price for retatrutide. There is no wholesale acquisition cost, copay, or insurer formulary placement, because there is no FDA-approved product. Lilly has not announced a price. This page does not guess one.

Anyone quoting a monthly cash price for “retatrutide” is not selling a lawful, FDA-approved retatrutide product. Compounded retatrutide is not a price for retatrutide — it is not a legal U.S. product. This site does not take pre-orders.

Lilly (23 July 2026) plans a Q1 2027 BLA filing. That is a planned filing, not an approval date, and not a launch price date. No PDUFA date has been assigned.

For status, read Retatrutide FDA Approval Status 2026: Not Approved. To get an email if Lilly files or if FDA acts, join this site’s waitlist (an email list run by NextGenGLP1, not a Lilly program).

What is available today is not retatrutide

If you want to talk with a clinician about a GLP-1 option that exists today, our primary partner is TrimRX: compounded GLP-1 + GIP through a telehealth consult. It is not Zepbound, not retatrutide, and compounded medication is not FDA-approved. Pricing is on TrimRX and can change; this page does not quote it.

Medvi is the secondary partner shown on the homepage. NextGenGLP1 may earn a commission on those links at no cost to you. Neither partner sells retatrutide.